Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 17;84(11):1104-13.
doi: 10.1212/WNL.0000000000001364. Epub 2015 Feb 13.

Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials

Ronald B Postuma  1 , Jean-Francois Gagnon  1 , Josie-Anne Bertrand  1 , Daphné Génier Marchand  1 , Jacques Y Montplaisir  2
Affiliations

Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials

Ronald B Postuma et al. Neurology. .

Abstract

Objective: To precisely delineate clinical risk factors for conversion from idiopathic REM sleep behavior disorder (RBD) to Parkinson disease, dementia with Lewy bodies, and multiple system atrophy, in order to enable practical planning and stratification of neuroprotective trials against neurodegenerative synucleinopathy.

Methods: In a 10-year prospective cohort, we tested prodromal Parkinson disease markers in 89 patients with idiopathic RBD. With Kaplan-Meier analysis, we calculated risk of neurodegenerative synucleinopathy, and using Cox proportional hazards, tested the ability of prodromal markers to identify patients at higher disease risk. By combining predictive markers, we then designed stratification strategies to optimally select patients for definitive neuroprotective trials.

Results: The risk of defined neurodegenerative synucleinopathy was high: 30% developed disease at 3 years, rising to 66% at 7.5 years. Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8), abnormal color vision (HR = 3.1), subtle motor dysfunction (HR = 3.9), and nonuse of antidepressants (HR = 3.5) identified higher risk of disease conversion. However, mild cognitive impairment (HR = 1.8), depression (HR = 0.63), Parkinson personality, treatment with clonazepam (HR = 1.3) or melatonin (HR = 0.55), autonomic markers, and sex (HR = 1.37) did not clearly predict clinical neurodegeneration. Stratification with prodromal markers increased risk of neurodegenerative disease conversion by 200%, and combining markers allowed sample size reduction in neuroprotective trials by >40%. With a moderately effective agent (HR = 0.5), trials with fewer than 80 subjects per group can demonstrate definitive reductions in neurodegenerative disease.

Conclusions: Using stratification with simply assessed markers, it is now not only possible, but practical to include patients with RBD in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Development of defined neurodegeneration in idiopathic RBD
Shown is the Kaplan-Meier plot of disease-free survival of patients with idiopathic REM sleep behavior disorder (RBD). Ticks indicate censoring events.
Figure 2
Figure 2. Predictive markers of neurodegeneration in idiopathic RBD
Shown is the Kaplan-Meier plot of disease-free survival of patients with idiopathic REM sleep behavior disorder (RBD), stratified according to presence of baseline markers: (A) olfaction, (B) color vision, (C) mild motor dysfunction, (D) autonomic dysfunction, (E) depression/anxiety, and (F) REM atonia loss. To mimic a clinical trial recruitment strategy, results are presented according to baseline assessment only (i.e., patients who develop a de novo marker abnormality over the course of the follow-up remain in the “marker-free” group). Solid line indicates patients with normal values, dashed line abnormal values. The 50% REM atonia (F) is for percentage tonic REM. Hazard ratios (HRs) are with Cox proportional hazards, adjusting for age and sex.
Figure 3
Figure 3. Combining predictive markers of neurodegeneration in idiopathic RBD
Shown is the Kaplan-Meier plot of disease-free survival of patients with idiopathic REM sleep behavior disorder (RBD), stratified according to combinations of baseline markers: (A) removing antidepressant-triggered RBD and age 55 years and older; (B) addition of olfaction and motor combined; (C) addition of olfaction and color vision combined; and (D) addition of motor and color vision combined. Solid line indicates patients with normal values, dashed lines mean that 1 of 2 measures is abnormal, dotted lines mean both measures are abnormal.
See this image and copyright information in PMC

Similar articles

  • Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.
    Postuma RB, Iranzo A, Hu M, Högl B, Boeve BF, Manni R, Oertel WH, Arnulf I, Ferini-Strambi L, Puligheddu M, Antelmi E, Cochen De Cock V, Arnaldi D, Mollenhauer B, Videnovic A, Sonka K, Jung KY, Kunz D, Dauvilliers Y, Provini F, Lewis SJ, Buskova J, Pavlova M, Heidbreder A, Montplaisir JY, Santamaria J, Barber TR, Stefani A, St Louis EK, Terzaghi M, Janzen A, Leu-Semenescu S, Plazzi G, Nobili F, Sixel-Doering F, Dusek P, Bes F, Cortelli P, Ehgoetz Martens K, Gagnon JF, Gaig C, Zucconi M, Trenkwalder C, Gan-Or Z, Lo C, Rolinski M, Mahlknecht P, Holzknecht E, Boeve AR, Teigen LN, Toscano G, Mayer G, Morbelli S, Dawson B, Pelletier A. Postuma RB, et al. Brain. 2019 Mar 1;142(3):744-759. doi: 10.1093/brain/awz030. Brain. 2019. PMID: 30789229 Free PMC article. Clinical Trial.
  • Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.
    Schenck CH, Montplaisir JY, Frauscher B, Hogl B, Gagnon JF, Postuma R, Sonka K, Jennum P, Partinen M, Arnulf I, Cochen de Cock V, Dauvilliers Y, Luppi PH, Heidbreder A, Mayer G, Sixel-Döring F, Trenkwalder C, Unger M, Young P, Wing YK, Ferini-Strambi L, Ferri R, Plazzi G, Zucconi M, Inoue Y, Iranzo A, Santamaria J, Bassetti C, Möller JC, Boeve BF, Lai YY, Pavlova M, Saper C, Schmidt P, Siegel JM, Singer C, St Louis E, Videnovic A, Oertel W. Schenck CH, et al. Sleep Med. 2013 Aug;14(8):795-806. doi: 10.1016/j.sleep.2013.02.016. Epub 2013 Jul 22. Sleep Med. 2013. PMID: 23886593 Free PMC article.
  • Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study.
    Joza S, Hu MT, Jung KY, Kunz D, Stefani A, Dušek P, Terzaghi M, Arnaldi D, Videnovic A, Schiess MC, Hermann W, Lee JY, Ferini-Strambi L, Lewis SJG, Leclair-Visonneau L, Oertel WH, Antelmi E, Sixel-Döring F, Cochen De Cock V, Liguori C, Liu J, Provini F, Puligheddu M, Nicoletti A, Bassetti CLA, Bušková J, Dauvilliers Y, Ferri R, Montplaisir JY, Lawton M, Kim HJ, Bes F, Högl B, Šonka K, Fiamingo G, Mattioli P, Lavadia ML, Suescun J, Woo KA, Marelli S, Martens KE, Janzen A, Plazzi G, Mollenhauer B, Fernandes M, Li Y, Cortelli P, Figorilli M, Cicero CE, Schaefer C, Guiraud L, Lanza G, Gagnon JF, Sunwoo JS, Ibrahim A, Girtler N, Trenkwalder C, Baldelli L, Pelletier A, Postuma RB; International REM Sleep Behavior Disorder Study Group. Joza S, et al. Brain. 2023 Aug 1;146(8):3258-3272. doi: 10.1093/brain/awad072. Brain. 2023. PMID: 36881989
  • Prodromal Parkinson's disease--using REM sleep behavior disorder as a window.
    Postuma RB. Postuma RB. Parkinsonism Relat Disord. 2014 Jan;20 Suppl 1:S1-4. doi: 10.1016/S1353-8020(13)00400-8. Parkinsonism Relat Disord. 2014. PMID: 24262156
  • REM Sleep Behavior Disorder in Parkinson's Disease and Other Synucleinopathies.
    St Louis EK, Boeve AR, Boeve BF. St Louis EK, et al. Mov Disord. 2017 May;32(5):645-658. doi: 10.1002/mds.27018. Mov Disord. 2017. PMID: 28513079 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schenck CH, Montplaisir JY, Frauscher B, et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 2013;14:795–806. - PMC - PubMed
    1. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): a 16-year update on a previously reported series. Sleep Med 2013;14:744–748. - PubMed
    1. Iranzo A, Tolosa E, Gelpi E, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013;12:443–453. - PubMed
    1. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 2012;27:617–626. - PubMed
    1. Postuma RB, Gagnon JF, Montplaisir JY. REM sleep behavior disorder: from dreams to neurodegeneration. Neurobiol Dis 2012;46:553–558. - PubMed

Publication types

Substances